Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases.
Mariangela ManfrediLieve Van HoovelsMaurizio BenucciRiccardo De LucaCarmela CocciaPamela BernardiniEdda RussoAmedeo AmedeiSerena GuiducciValentina GrossiXavier BossuytCarlo PerriconeMaria InfantinoPublished in: Journal of personalized medicine (2023)
The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.
Keyphrases
- cardiovascular disease
- oxidative stress
- induced apoptosis
- rheumatoid arthritis
- multiple sclerosis
- type diabetes
- systematic review
- cell cycle arrest
- drug induced
- papillary thyroid
- squamous cell carcinoma
- skeletal muscle
- cardiovascular events
- adipose tissue
- squamous cell
- endoplasmic reticulum stress
- coronary artery disease
- binding protein
- risk factors
- cell proliferation